Dr. Kurt Zatloukal, national node director of the Bio-Banking and Bio-Molecular Resources Research Infrastructure of Austria (BBMRI Austria), discusses the challenges of collaboration between the private and academic pharmaceutical sectors and the importance of their work in advancing pharmaceutical innovation. Furthermore, he looks into the growing trend of personalised medicines and the importance of Austria, and more specifically Graz, as the centre point for BBMRI Europe´s (BBMRI-ERIC) operations.
As the national node director, could you introduce our international readers to BBMRI Austria?
"Personalised medicine is one of the key drivers in the pharma industry, but I must admit that I am concerned about the sustainability of the current status of personalised medicine."
